Jaguar Health, Inc.
crofelemer
rare intestinal failure diseases
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on crofelemer for rare intestinal failure diseases is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“the Company for our crofelemer-based prescription drug candidate for rare intestinal failure diseases.”